Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics Biotech Inc. today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK.

20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd., JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.

18 Apr 2011

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

Study: Significant variation found in results of bowel cancer surgery across English NHS hospitals

There is worrying variation in the results of bowel cancer surgery across NHS hospitals in England with some having many more patient deaths immediately after surgery than others, according to new research funded by Cancer Research UK and published today in Gut.

12 Apr 2011

Bowel cancer surgery survival rates “worrying” experts

In a new study that looked into post-operative death rates for one of the most common cancers, trends look worrying. On average 6.7% of patients died within a month of undergoing surgery for bowel cancer in England between 1998 and 2006. Patients face a seven-fold higher risk of dying after surgery in some NHS trusts than others, the study shows.

11 Apr 2011

CINJ experts to comment on vaccine therapy and biomedical informatics

April marks National Cancer Control Awareness Month, which focuses on the importance of prevention, treatment, and research. Making significant contributions in all of these areas is The Cancer Institute of New Jersey, one of the nation's 40 Comprehensive Cancer Centers as designated by the National Cancer Institute and the only such center in New Jersey.

11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Two new studies on Veterans Affairs health care system

As recently as the 1990s, the Veterans Affairs health care system had a subpar reputation for quality, but two new studies of standard quality metrics, both led by Amal Trivedi, assistant professor of community health at Brown University and a physician at the Providence VA Medical Center, show that the system that cares for more than 5 million patients has improved markedly in the last decade.

8 Apr 2011

Cancer screening updates

Everyone in England aged 55 to 59 will be invited for a new test which could dramatically cut their chances of developing bowel cancer. This new test could save an extra 3,000 lives every year after the UK National Screening Committee gave the nod for it to be added to the NHS programme. The test known as Flexible sigmoidoscopy (FS) differs to the current faecal occult blood (FOB) test, which relies on people sending off stool samples.

7 Apr 2011

Alcohol raises risk of cancers: Study

This comes from a large Europe-wide study published in the British Medical Journal that found that one-in-10 of all cancers in men and one-in-33 of all cancers in women are caused by past or current alcohol intake. For alcohol-related cancers, one-in-three in men and one-in-20 in women are caused by any excessive drinking. According to cancer charities say people should limit their drinking to lower the risk.

7 Apr 2011

DSP, BBI sign license agreement for BBI608

Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

7 Apr 2011

Robotic-assisted keyhole surgery tested for bowel cancer

A robotic system that promises to improve the quality of 'keyhole' bowel cancer surgery is being put to the test for the first time.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

Estrogen therapy for menopause, study looks at risks-benefits

...

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011